Fibroblastic niches in action: CCL19+ reticular cells drive anti-tumor immunity in lung cancer [0.03%]
纤维状生态位的作用：CCL19+网状细胞驱动肺癌的抗肿瘤免疫反应
Alessandro Ianni,Alejandro Vaquero,Thomas Braun
Alessandro Ianni
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs [0.03%]
通过代谢药物针对乳腺癌中的PI3K抑制剂耐药性问题
Niklas Gremke,Isabelle Besong,Alina Stroh et al.
Niklas Gremke et al.
Activating PIK3CA mutations, present in up to 40% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (Her2-) breast cancer (BC) patients, can be effectively targeted with the alpha isoform-specific PI3K in...
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy [0.03%]
BCL2家族：从细胞凋亡机制到靶向治疗的新进展
Meike Vogler,Yannick Braun,Victoria M Smith et al.
Meike Vogler et al.
The B cell lymphoma 2 (BCL2) protein family critically controls apoptosis by regulating the release of cytochrome c from mitochondria. In this cutting-edge review, we summarize the basic biology regulating the BCL2 family including canonica...
An unexpected player in organ tropism: aspartate functions as signalling molecule to drive lung metastasis [0.03%]
器官特异性的意外参与者：天冬氨酸作为信号分子驱动肺转移
Felix C E Vogel,Almut Schulze
Felix C E Vogel
Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study [0.03%]
KN026（一种双特异性抗HER2抗体）与KN046（一种抗CTLA4/PD-L1抗体）联用治疗晚期HER2阳性非乳腺癌患者的疗效和安全性：一项Ib期和II期研究的联合分析
Dan Liu,Jifang Gong,Jian Li et al.
Dan Liu et al.
To evaluate the efficacy and safety of KN026, a novel bispecific HER2 (ECD2 and ECD4) antibody, plus KN046, a PD-L1, and CTLA4 bispecific antibody, in patients with advanced HER2-positive solid tumors. We conducted two sequentially designed...
Massively parallel interrogation of human functional variants modulating cancer immunosurveillance [0.03%]
大规模并行检测人类功能变异调节癌症免疫监视
Ying Liu,Yongshuo Liu,Xuran Niu et al.
Ying Liu et al.
Anti-PD-1/PD-L1 immune checkpoint blockade (ICB) therapy has revolutionized clinical cancer treatment, while abnormal PD-L1 or HLA-I expression in patients can significantly impact the therapeutic efficacy. Somatic mutations in cancer cells...
Cytosolic nucleic acid sensing as driver of critical illness: mechanisms and advances in therapy [0.03%]
细胞质核酸感应作为驱动重症的机制及其治疗进展
Zhaorong Chen,Rayk Behrendt,Lennart Wild et al.
Zhaorong Chen et al.
Nucleic acids from both self- and non-self-sources act as vital danger signals that trigger immune responses. Critical illnesses such as acute respiratory distress syndrome, sepsis, trauma and ischemia lead to the aberrant cytosolic accumul...
Photodynamic gel-bombs enhance tumor penetration and downstream synergistic therapies [0.03%]
光动力凝胶炸弹可提高肿瘤渗透性及下游联合治疗效果
Xiaole Bai,Fanliang Meng,Xuejiao Wang et al.
Xiaole Bai et al.
Nanoparticle-based drug delivery system remains a significant challenge in the current treatment of solid tumors, primarily due to their limited penetration capabilities. Herein, we successfully engineer photodynamic gel-bombs (DCM@OPR) cap...
Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results [0.03%]
单核细胞系肿瘤浸润预测晚期治疗前软组织肉瘤的免疫放射治疗反应：二期试验结果
Antonin Levy,Daphné Morel,Matthieu Texier et al.
Antonin Levy et al.
Immunoradiotherapy holds promise for improving outcomes in patients with advanced solid tumors, including in soft-tissue sarcoma (STS). However, the ideal combination of treatment modalities remains to be determined, and reliable biomarkers...
Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics [0.03%]
系统性红斑狼疮：发病机理、诊断、预防和治疗的最新见解
Xiaofeng Dai,Yuting Fan,Xing Zhao
Xiaofeng Dai
Systemic lupus erythematosus (SLE) is a chronic inflammatory illness with heterogeneous clinical manifestations covering multiple organs. Diversified types of medications have been shown effective for alleviating SLE syndromes, ranging from...